Navigation Links
Numira Biosciences Names New Board Member
Date:3/5/2008

Drug discovery and development veteran Paul Grint, M.D. brings extensive

experience to Numira

IRVINE, Calif., March 5 /PRNewswire/ -- Numira Biosciences announced the appointment of Paul Grint, M.D., to its Board of Directors.

Currently, Dr. Grint serves as the Chief Medical Officer and Head of Development at Kalypsys, Inc., a drug discovery and development company based in San Diego, CA. Prior to Kalypsys, he held senior management positions at Zephyr Sciences, Pfizer Global Research & Development, IDEC Pharmaceuticals, and Schering-Plough. Additionally, he is a member of the Board of Directors at Illumina Inc. and serves as Chairman of the Advisory Council of the Keck Graduate Institute.

"We are very pleased to have attracted an industry leader of Dr. Grint's caliber," said Michael Beeuwsaert, President and CEO of Numira. "His extensive background in drug discovery and development will be invaluable to us as we head into our next phase of growth."

About Numira Biosciences

Numira Biosciences is a specialty R&D tools company focused on leveraging advances in genetics and molecular imaging to create a catalog of novel, high-value products that provide researchers with unprecedented insight into genomics, developmental biology, mechanisms of disease, drug efficacy, and toxicity.

For more information, please visit the company's website at http://www.numirabio.com.


'/>"/>
SOURCE Numira Biosciences
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
4. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
5. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
6. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
7. Anaptys Biosciences Raises Over $33 Million in Series B Financing
8. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
9. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
10. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
11. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)..., ALEXANDRIA, Va., Jan. 8 /PRNewswire-USNewswire/ ... Organization along with several national leadersh...rding the principles of hospice care and protectio...ns standing together in sharing this unified messa...tion of Hospice and Palliative Medicine, Hospice a...
(Date:1/8/2009)..., California Assembly Member Tom Torlakson Introdu...swire-USNewswire/ -- Today, Lung Cancer Alliance...ember Tom Torlakson (D-11th District) for his cont...ing funding for lung cancer research. For the thi...ung cancer research is being considered in the Cal...
(Date:1/8/2009)...view says it lowered bad cholesterol more effectiv...lthDay News) -- After nearly a year of review, U.S...ed the continued use of the controversial choleste...Drug Administration said there was no significant ...ients taking Vytorin and patients taking the drug ...
(Date:1/8/2009)..., First Announced Acquisition in 2009 Continues Gr... IPC The Hospitalist Comp...spitalist physician group practice company, announ...ctice of Midwest Acute Care Consultants, Inc. (MAC...nts continued expansion in the St. Louis market, w...
Breaking Medicine News(10 mins):Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 3Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 4Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 5Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 6Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 7Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2
...ational TB Control Programme (RNTCP) aims at widen...uality treatment and diagnostic services to all tu...0 % of HIV-positive people are more prone to contr...amily Welfare Minister Anbumani Ramadoss plan to t...
...nducted by Steven M. Kurtz, of Exponent Inc., a Ph...ting firm//, there is an increase in demand for ar...artificial joints needed to replace damaged knees ...e study showed that the demand for artificial hips...
...ts had captured the market and minds of various pe...iny. // A number of detox products are to be inve... report by the BBC which drew its attention to som...he Medical Health Care Products Regulatory Agency ...
...ar, Nitish Kumar assured that the Bihar Government...ing spread of AIDS/HIV in the state //, addressing...ma foundation, Samyak and the National Aids Contro...oncern over the explosive prevalence of HIV/AIDS i...
Other Medicine News:Health News:India to Implement National Action Plan against TB-HIV 2
(Date:1/6/2009)...from prior U.S., U.K. and China Trials , , SAN .... (VTI), a development stage company targeting liv... begun for a randomized, controlled, multi-center,...orporeal Liver Assist Device (ELAD) as a treatment... three protocols. The study is open for enrollment...
(Date:1/6/2009)...-- Cequent Pharmaceuticals, a pioneer in the devel...atments to prevent and treat human disease, announ...essful toxicology study of its candidate CEQ501, a...ng the primary oncogene (beta-catenin, CTNNB1) in ...herited gastrointestinal disease that causes hundr...
(Date:1/5/2009)...re/ -- Women undergoing in vitro,fertilization (I...t early,pregnancy, but the intramuscular injectio...ul for patients. Formulations of progesterone med... injection or vaginal suppository may offer,simil... With patient well-being a constant focus, Fertili...
(Date:12/27/2008)...wire/ -- According to the latest,science, resvera... doses of,resveratrol plus an array of antioxidan...es of aged, red wine, rather than resveratrol alon...in/prnh/20080603/LATU039 ) , The most rece...o prolong,the life of laboratory mice. In fact, ...
Breaking Medicine Technology:ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 3Gene Variant Doubles Risk of Prostate Cancer in Black Men 5399 1Gene Variant Doubles Risk of Prostate Cancer in Black Men 5399 2Palatin Technologies to Present at the Acumen BioFin Rodman 26 Renshaw 9th Annual Healthcare Conference 5397 115th Anniversary Celebration Shoot For a Cure Event Slated for Nov 8 5395 1Scientists discover novel way to remove iron from ferritin 1088 1
...uly 11, 2007 /PRNewswire-FirstCall/ -- On Wednesda...astern/10:30 p.m.,Central European Time members of...ill host a conference call to discuss today,s,anno...I RAPID trial,comparing CHOP-R to CPOP-R, in which...dard CHOP-R, in first-line treatment of patients,w...
...ion ,Automation continues to gain importance in...ing test consolidation, rising demands from clinic...ing shortage of licensed medical technologists. Ul...lity automation solutions are better equipped to m...t of overall laboratory automation (e.g. sample pr...
Other Medicine Technology:Cell Therapeutics, Inc. Management to Discuss Today's Announcement,of Interim Pixantrone Study Results 2Optimizing Quality Control Data Management 2Optimizing Quality Control Data Management 3Optimizing Quality Control Data Management 4Optimizing Quality Control Data Management 5
2.5 mm cups angled 50 degrees, 10 mm from angle to tip. Serrated handle with polished finish.
Two rows of teeth on jaws provide a firm purchase on the nucleus fragment for removal. Flat handle with dull finish.
Puntenney curved forceps, curved, smooth 10 mm platforms.
Curved, very delicate, smooth jaws with platforms., ,Straight, very delicate, smooth jaws with platforms.
Medicine Products: